Sign In
Buy NVO
$47.41
-0.0100 (-0.0211%)
At Close: Jun 24, 2026
Lexaria Says Oral GLP-1 Cuts Side Effects Nearly 50% Versus Novo Nordisk's Rybelsus
12:06pm, Tuesday, 23'rd Dec 2025
Lexaria Bioscience Corp. (NASDAQ: LEXX) on Tuesday provided an update on its Phase 1b, 12-week chronic study GLP-1-H24-4, recently completed in Australia, focusing on 4 DehydraTECH ( DHT) study arms r
Novo Nordisk gets US approval for Wegovy obesity pill
11:58am, Tuesday, 23'rd Dec 2025
Novo Nordisk won approval to sell a pill version of its blockbuster obesity shot Wegovy in the US, a crucial step in its effort to defend its market share from rival Eli Lilly. President and CEO Mike
Novo Nordisk Wins FDA Nod for Oral Wegovy in Obesity, Stock Up
11:50am, Tuesday, 23'rd Dec 2025
NVO stock up as it wins FDA approval for oral Wegovy in obesity, becoming the first oral GLP-1 RA indicated for weight management.
Could Novo Nordisk's New Weight-Loss Pill Be Just What Its Stock Needs?
11:45am, Tuesday, 23'rd Dec 2025
Could a new weight-loss pill be just what Novo Nordisk (NVO) needs to revive its stock?
Novo Nordisk Loses Weight-Loss Lead as Lilly Gains Ground
11:27am, Tuesday, 23'rd Dec 2025
Analysts tracking the global obesity-drug market suggest Novo Nordisk (NVO) is navigating a materially more competitive phase after its early leadership in GLP-
FDA approves first GLP-1 pill for obesity from Wegovy maker Novo Nordisk
11:16am, Tuesday, 23'rd Dec 2025
CNBC's Annika Kim Constantino reports on the FDA's approval of the first GLP-1 pill for obesity from Wegovy maker Novo Nordisk.
Novo Nordisk vs. Amgen: Which Healthcare Stock Is the Smarter Choice?
11:16am, Tuesday, 23'rd Dec 2025
NVO and AMGN square off as GLP-1 leadership, pipeline depth, and diversification set up a compelling healthcare stock comparison.
Novo Nordisk Stock Soars on FDA-Cleared GLP-1 Pill
10:38am, Tuesday, 23'rd Dec 2025
Novo Nordisk A/S (NYSE:NVO) stock is up 8.8% to trade at $52.37 at last check, after the biopharmaceutical giant received approval from the U.S. Food & Drug Administration (FDA) for the first ever GLP
Novo Nordisk's Christmas Gift To Shareholders: The Wegovy Pill Has Been Approved
10:30am, Tuesday, 23'rd Dec 2025
Novo Nordisk A/S secured FDA approval for the oral Wegovy pill, marking a pivotal catalyst for a 2026 turnaround. The Wegovy pill delivers 16.6% weight loss in 64 weeks, outpacing Eli Lilly's Orforgli
Novo Going 'All-In' With Wegovy Weight Loss Pill
09:42am, Tuesday, 23'rd Dec 2025
The US will let Novo Nordisk A/S sell it blockbuster weight loss drug Wegovy in a pill form. Millions of people already take the shot.
Stock Futures Cool Off After Delayed GDP Data
09:14am, Tuesday, 23'rd Dec 2025
Stock futures are quietly lower as investors unpack previously delayed GDP data for the third quarter
Novo CEO Says Wegovy Pill Is Safe and Will Be Widely Available
09:06am, Tuesday, 23'rd Dec 2025
Novo Nordisk President and CEO Mike Doustdar says Christmas has come early with US approval of its Wegovy weight loss pill. He says the company is going "all-in" and they are super excited to be the f
Eli Lilly Vs. Novo Nordisk: Which Stock Could Lead Pharma's 2026 Comeback
08:54am, Tuesday, 23'rd Dec 2025
As investors look beyond mega-cap tech for the next leg of growth, pharma is quietly moving back into focus — and no two names capture that shift better than Eli Lilly And Co (NYSE: LLY) and Novo No
5 Things to Know Before the Stock Market Opens
08:40am, Tuesday, 23'rd Dec 2025
Stock futures are little changed Tuesday morning after three consecutive sessions of solid gains for major indexes; gold and silver are sustaining their rally, with prices of the precious metals hitti
Novo Nordisk's new obesity pill, Alphabet's data center deal, the end of EV euphoria and more in Morning Squawk
07:46am, Tuesday, 23'rd Dec 2025
Regulators approved the first-ever pill for treating obesity from Novo Nordisk. Alphabet will acquire data center company Intersect for $4.75 billion in cash and assume its debt.
